Japan
Kyushu University - Kyushu University Hospital
Lung cancer, MET, acquired resistance, cabozantinib, clinical trial
Epidermal growth factor receptor (EGFR), Tyrosine kinase inhibitor, Circulating tumor DNA, chemotherapy, Osimertinib
Epidermal growth factor receptor (EGFR)Tyrosine kinase inhibitorOsimertinibTumor sizePrimary lesion